 Patients undergo biopsy for correlative studies. Samples are analyzed for estrogen receptor and progesterone receptor status, and molecular endpoints CK 56, CK14, p53, BRCA, and EGFR by RT-PCR, immunohistochemistry, protein expression, and gene expression profiling. 